Adaptive Biotechnologies Corp

Latest Report Overview

Adaptive Biotechnologies Corp (ADPT) reported For the quarterly period ended June 30, 2026 (Issuer fiscal Q2 FY2026) revenue of $72 million with diluted EPS of $-0.25 and net income of $-40 million. Operating margin was -21.9%, and free cash flow was $-8 million for the period. Management continues to prioritize the expansion of the clonoSEQ clinical footprint and the integration of the platform into the biopharmaceutical drug discovery process. Growth is primarily driven by test volume expansion in clinical settings and strategic collaborations, though operating expenses related to R&D and commercial infrastructure remain high. The company's focus remains on balancing growth with the necessity of reaching a sustainable operating cash flow inflection point. Liquidity remains a key focus area, with cash and cash equivalents of $169.87 million as of the period end. While the revenue growth trajectory is positive, the company continues to manage its debt position of approximately $334.88 million. Outlook and guidance emphasize continued investment in the platform's proprietary data capabilities to maintain a competitive lead in immune medicine research.

Key Takeaways for Adaptive Biotechnologies Corp

• Reported Q2 2026 revenue of $71.55 million, an increase of 21.5% YoY, signaling continued market demand for immune medicine solutions.
• Gross margins remained robust at 71.8%, highlighting the scalability of the sequencing platform despite a net loss of $39.79 million for the quarter.
• Operating expenses remain the primary drag on profitability, with R&D expenditures at $18.31 million for the quarter, reflecting sustained investment in platform innovation.
• Cash position of $169.87 million and debt levels of $334.88 million underscore the need for effective capital allocation and continued growth to manage the balance sheet.
• The ongoing challenge is to translate strong platform metrics and partnerships into consolidated profitability and positive free cash flow, which remains volatile.

What Does Adaptive Biotechnologies Corp Do?

Adaptive Biotechnologies Corp is an immune medicine company that translates the genetics of the adaptive immune system into clinical products to diagnose and treat diseases. The company provides a unique platform for reading and analyzing T-cell and B-cell receptors (TCRs/BCRs), which function as the body's primary sensors for disease. Its clinical diagnostic product, clonoSEQ, is used for monitoring minimal residual disease (MRD) in patients with lymphoid cancers, providing a high-sensitivity test that informs clinical decisions. Beyond diagnostics, the company provides immunoSEQ, a comprehensive research and drug discovery platform that partners with pharmaceutical and biotech companies to identify clinical candidates, optimize biomarkers, and understand patient responses to therapies. Operating primarily in the United States, the company serves clinicians, hospitals, and life sciences organizations, scaling its impact through proprietary data assets and an integrated clinical-research flywheel that continuously builds its internal immune medicine database.

Growth Drivers for Adaptive Biotechnologies Corp

• Expansion of clonoSEQ clinical penetration into broader lymphoid cancer diagnostic markets.
• Increased utilization of the immunoSEQ platform by pharmaceutical partners for biomarker discovery and patient stratification.
• Strategic partnerships with global biotech firms to integrate immune profiling into clinical trial designs.
• Continuous platform R&D to improve sequencing efficiency and analytical speed, lowering cost per test.
• Development of novel clinical applications for the platform beyond current lymphoid cancer diagnostic indications.